Cargando…
Innate Immune System and Multiple Sclerosis. Granulocyte Numbers Are Reduced in Patients Affected by Relapsing-Remitting Multiple Sclerosis during the Remission Phase
Background: Multiple sclerosis (MS) is a neurodegenerative disease that affects the central nervous system. The cause of MS is still unknown, and the role of innate immunity is still poorly understood. Objective: The goal of this study was to understand whether, compared to healthy controls, the ele...
Autores principales: | Pavelek, Zbyšek, Angelucci, Francesco, Souček, Ondřej, Krejsek, Jan, Sobíšek, Lukáš, Klímová, Blanka, Šarláková, Jana, Halúsková, Simona, Kuča, Kamil, Vališ, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290702/ https://www.ncbi.nlm.nih.gov/pubmed/32422897 http://dx.doi.org/10.3390/jcm9051468 |
Ejemplares similares
-
Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis
por: Peterka, Marek, et al.
Publicado: (2023) -
Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor
por: Pavelek, Zbysek, et al.
Publicado: (2023) -
The role of the immune system and the biomarker CD3 + CD4 + CD45RA−CD62L− in the pathophysiology of migraine
por: Pavelek, Zbyšek, et al.
Publicado: (2020) -
Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry
por: Vališ, Martin, et al.
Publicado: (2022) -
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)